Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
Colon cancer is a cancer that originates in the colon or rectum, part of the large intestine. Alfa Cytology is a world leader in the development of cancer vaccines. With our extensive experience and advanced platform, we are confident that we can provide the best vaccine development services for colon cancer.
Most colorectal cancer is caused by aging and poor lifestyle factors in the body, and only a small number of cases are caused by an underlying genetic disease. Some of the risk lifestyle factors include smoking, obesity, diet, and lack of exercise. Another risk factor is inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Signs and symptoms may include feeling tired, weight loss, and blood in the stool. It usually starts as a benign tumor, usually in the form of a polyp, and becomes cancerous over time.
Therapy for colon cancer may include various combinations of surgery, radiation, chemotherapy, and targeted therapy. Regardless of the progress made in the management of therapies for colon cancer, it remains the third most common cause of cancer death worldwide. Among the therapies, the colon cancer vaccine from the perspective of activating and amplifying immune response is one of the hot topics. Here are some new cancer therapies targeting vaccines.
The complex microbial community in the colon is critical for maintaining homeostasis, supporting the intestinal barrier, regulating metabolic function, and controlling immune responses. Probiotics can play an important role in immune regulation. Lactobacillus Rhamnosus and Bifidobacterium Longum were coated on lipid membranes to reduce the loss of activity and better colonize the colon. Combining probiotics with cancer vaccines will have a synergistic effect.
The disadvantages of traditional chemotherapeutic agents are poor solubility, low permeability, non-specific targeting, low accumulation within the tumor, and dose-dependent toxicity to normal tissue. In response to the above problems, cancer vaccines need to have a powerful immune effect and also need to try to overcome these problems. Therefore, it is important to develop appropriate vaccine delivery systems.
For example, fluoroalkane-grafted polyethyleneimine (F-PEI), as a novel vaccine delivery system, can promote intracellular mRNA delivery and activate Toll-like receptor 4 (TLR4) mediated signaling pathways. Vaccines formed by self-assembly F-PEI and tumor antigen-coding mRNA can induce dendritic cells (DC) to mature and trigger effective antigen presentation without additional adjuvants, thus triggering an anti-tumor immune response.
Alfa Cytology is working on developing therapeutic colon cancer vaccines based on different targets, methods, or effective delivery systems.
Alfa Cytology is committed to the research and development of cancer vaccines, from the discovery of cancer antigens, and the development of different types of vaccines, to vaccine research for different cancer types, providing one-stop services. If you are interested in our service, please contact us.